Kidswell Bio Corporation (TSE: 4584)
Health Care · Biotechnology · JP
¥170.00
+4.29% today · -28.9% 1Y
Kidswell Bio Corporation (TSE: 4584) operates in the Biotechnology industry within the Health Care sector. The company is valued at $54.09M and employs 32 people.
Over the last twelve months the share price has lost 28.9%, trading between 125.00 and 320.00.
Tweenvest scores Kidswell Bio Corporation across four factors: quality 50/100, value 89/100. Its strongest factor is value.
4584 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $54.09M
- Revenue (TTM)
- $37.76M
- P/E
- —
- EPS
- -7.56
- Dividend yield
- —
- Beta (5Y)
- 1.19
- 52-week high
- ¥320.00
- 52-week low
- ¥125.00
- Avg volume (3M)
- —
- Shares outstanding
- 50.58M
- Employees
- 32
- Next earnings
- —
About Kidswell Bio Corporation
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding in July 2021, maintains a robust pipeline of therapeutic candidates. This includes GND-004, designed for both ophthalmic conditions and oncology, and GND-007, aimed at immunological disorders. Their portfolio also features a range of antibodies being developed for cancer therapies. Further expanding its research, the GBS series encompasses GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for eye-related ailments; GBS-008 for infectious diseases; and GBS-011 for renal conditions. Additionally, Kidswell Bio is progressing GCT-101 for alveolar clefts, GCT-102 for congenital isolated hypoganglionosis, alongside other investigational products addressing ophthalmologic disorders, cerebral palsy, peripheral nerve palsy, fractures, and spinal cord injuries.
- ISIN
- JP3386460004
- Founded
- 2001
- Listed since
- Nov 30, 2012
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.